Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pelosi aide expects health care reform by Easter

This article was originally published in The Tan Sheet

Executive Summary

Congress "can pass a reconciliation bill and have a health reform bill by Easter recess," says Wendell Primus, a top aide for Speaker of the House Nancy Pelosi, D-Calif. Primus, a senior Pelosi advisor on budget and health issues who spoke at Academy Health's National Health Policy Conference in Washington Feb. 9, said the only way to pass a bill is for the House to use the budget reconciliation process to change a provision in the Senate version with which the House Democratic majority disagrees (1"The Tan Sheet" Jan. 18, 2010). Republican congressional aides at the conference said they could support passing a series of smaller health-focused reform bills, such as Medicare reforms or other targeted refinements. But a Democratic aide from the Senate Finance Committee suggested Democrats are unlikely to support that approach

You may also be interested in...

CHPA Reminds Congress OTC Benefits Belong In Health Care Reform

The Consumer Healthcare Products Association pushes for broader OTC drug benefits in health care reform legislation while urging the House to adopt language from the Senate bill that allows at least for limited coverage of OTCs in health savings and flexible spending accounts

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.







Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts